As downregulation of the CCL19/CCR7 axis has been observed in metastatic breast cancer compared to the primary tumor (Szekely et al., 2018) and CCL19 suppresses angiogenesis and proliferation of several other types of cancers (Xu et al., 2018; Zhou et al., 2020), it is biologically plausible that CCL19 inhibits breast cancer metastasis through similar AIM2 and Met/ERK/Elk-1/HIF-1α/VEGF-A pathways (Chen et al., 2006) and therefore increases patient survival. Here, CCR7 is linked to neoplasm.